The relevance “per se“ of p38β in cancer treatments, as a putative target, has been demonstrated in the previously mentioned experimental model of pancreatic cancer by using specific p38β inhibitory peptides [85] but, unfortunately, no other examples of specific targeted therapy based on p38β have been reported so far. Here, MAPK11 is linked to familial pancreatic carcinoma.